<DOC>
	<DOCNO>NCT02480101</DOCNO>
	<brief_summary>This single centre phase I , double-blind placebo-controlled study ass reactogenicity , safety immunogenicity live monovalent A/17/Anhui/2013/61 ( H7N9 ) influenza vaccine healthy male female adult , 18 49 year age .</brief_summary>
	<brief_title>Reactogenicity , Safety Immunogenicity LAIV H7N9 Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Legal male female adult 18 49 year age enrollment visit . Literate willing provide write informed consent . A sign informed consent . Free obvious health problem , establish medical history screening evaluation , include physical examination . Capable willing complete diary card willing return followup visit Willing comply rule isolation unit ( include willing able take oseltamivir influenza antiviral medication , recommend study physician ) . For female , willing take reliable birth control measure day 56 . Participation another clinical trial involve therapy within previous three month plan enrollment trial period study . Receipt nonstudy vaccine within four week prior enrollment refusal postpone receipt vaccine four week study completion . Practice nasal irrigation regular basis within past six month engage nasal irrigation within two week prior enrollment . Recent history frequent nose bleeds ( 5 within past year ) . Clinically relevant abnormal paranasal anatomy . Recent history ( within past month ) rhino sinus surgery , surgery traumatic injury nose . Current recent ( within two week enrollment ) acute respiratory illness without fever . Other acute illness time study enrollment . Receipt immune globulin blood product within three month prior study enrollment plan receipt product period subject participation study . Chronic administration ( define 14 consecutivelyprescribed day ) immunosuppressant immunemodulating therapy within six month prior study enrollment ( corticosteroid , mean prednisone equivalent , 0.5 mg per kg per day ; topical steroid allow , exclusive nasal . ) Participation previous trial H7 H5 contain influenza vaccine . History bronchial asthma . Hypersensitivity allergy reaction previous administration vaccine . History wheeze past receipt live influenza vaccine . Other AE follow immunization ( body temperature 40Â°C , collapse , nonfebrile seizure , anaphylaxis ) , least possibly relate previous receipt vaccine ( influenza ) . Suspected known hypersensitivity study vaccine component , include chicken egg protein . Seasonal ( autumnal ) hypersensitivity natural environment . Acute chronic clinically significant pulmonary , cardiovascular , hepatic , metabolic , neurologic , psychiatric renal functional abnormality , determine medical history , physical examination clinical laboratory screening test , opinion investigator , might interfere study objective . Subjects physical examination finding clinical laboratory screening result would grade 2 high AE severity grade scale exclude entry study exclude receipt dose two study vaccine placebo . History leukemia blood solid organ cancer . History thrombocytopenic purpura know bleed disorder . History seizure . Known suspect immunosuppressive immunodeficient condition kind , include HIV infection . Known chronic HBV HCV infection . Known tuberculosis infection evidence previous tuberculosis exposure . History chronic alcohol abuse and/or illegal drug use . Claustrophobia sociophobia . Pregnancy lactation ( negative pregnancy test require administration study vaccine placebo woman childbearing potential ) . Any condition , opinion investigator , would increase health risk subject he/she participates study would interfere evaluation study objective . Allergic , include anaphylactic , reaction introduction vaccine subject 's medical history ( flu vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>influenza vaccine pandemic</keyword>
</DOC>